| First Author | Saito M | Year | 2019 |
| Journal | J Invest Dermatol | Volume | 139 |
| Issue | 7 | Pages | 1459-1469 |
| PubMed ID | 30684556 | Mgi Jnum | J:294488 |
| Mgi Id | MGI:6456462 | Doi | 10.1016/j.jid.2018.12.027 |
| Citation | Saito M, et al. (2019) A Polymorphic Variant in p19(Arf) Confers Resistance to Chemically Induced Skin Tumors by Activating the p53 Pathway. J Invest Dermatol 139(7):1459-1469 |
| abstractText | Identification of the specific genetic variants responsible for the increased susceptibility to familial or sporadic cancers is important. Using a forward genetics approach to map such loci in a mouse skin cancer model, we previously identified a strong genetic locus, Stmm3, conferring resistance to chemically induced skin papillomas on chromosome 4. Here, we report the cyclin-dependent kinase inhibitor gene Cdkn2a/p19(Arf) as a major responsible gene for the Stmm3 locus. We provide evidence that the function of Stmm3 is dependent on p53 and that p19(ArfMSM) confers stronger resistance to papillomas than p16(Ink4aMSM)in vivo. In addition, we found that genetic polymorphism in p19(Arf) between a resistant strain, MSM/Ms (Val), and a susceptible strain, FVB/N (Leu), alters the susceptibility to papilloma development, malignant conversion, and the epithelial-mesenchymal transition. Moreover, we demonstrated that the p19(ArfMSM) allele more efficiently activates the p53 pathway than the p19(ArfFVB) allele in vitro and in vivo. Furthermore, we found polymorphisms in CDKN2A in the vicinity of a polymorphism in mouse Cdkn2a associated with the risk of human cancers in the Japanese population. Genetic polymorphisms in Cdkn2a and CDKN2A may affect the cancer risk in both mice and humans. |
